Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.

被引：3
|
作者：
Freedland, Stephen J. [1 ]
Sandin, Rickard [2 ]
Sah, Janvi [3 ]
Emir, Birol [4 ]
Mu, Qiao [3 ]
Ratiu, Anna [3 ]
Hong, Agnes [5 ]
Serfass, Lucile [6 ]
Tagawa, Scott T. [7 ]
机构：
[1] Vet Affairs Hlth Care Syst, Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA USA
[2] Pfizer AB, Sollentuna, Sweden
[3] STATinMED Res, Ann Arbor, MI USA
[4] Pfizer Inc, New York, NY USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Pfizer Inc, Paris, France
[7] New York Presbyterian Hosp, Weill Cornell Med Div Hematol & Med Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.
    Wallis, Christopher J. D.
    Satkunasivam, Raj
    Nguyen, David-Dan
    Aminoltejari, Khatereh J. D.
    Hird, Amanda Elizabeth
    Roy, Soumyajit
    Morgan, Scott C.
    Malone, Shawn
    Shayegan, Bobby
    Breau, Rodney H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 69 - 69
  • [42] Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a US health insurance database.
    Swami, Umang
    Hong, Agnes
    El-Chaar, Nader N.
    Nimke, David
    Ramaswamy, Krishnan
    Bell, Elizabeth J.
    Sandin, Rickard
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] A real-world registry of patients with metastatic castration-resistant prostate cancer (mCRPC): REMPRO study.
    Gonzalez, Francisco
    Kodagali, Rohit
    Tung, Teresa
    Masoud, Mohamed
    Rajadhyaksha, Viraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Prognostic significance of docetaxel (D) plus androgen-deprivation therapy (ADT) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) according to extent of disease: A study of real-world data
    Notario, L.
    Piulats, J. M.
    Sala, N.
    Ferrandiz, U.
    Gonzalez, A.
    Etxaniz, O.
    Villa, S.
    Buisan, O.
    Boladeras, A.
    Heras, L.
    Del Carpio, L.
    Rosello, A.
    Barretina, P.
    Fina, C.
    Pardo, J. C.
    Suarez, J. M.
    Comet, J.
    Garcia del Muro, X.
    Esteve, A.
    Font, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S532 - S532
  • [45] Real-world (RW) comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus enzalutamide (ENZ)
    Lowentritt, Benjamin H.
    Khilfeh, Ibrahim
    Pilon, Dominic
    Du, Shawn
    Rossi, Carmine
    Kinkead, Frederic
    Diaz, Lilian
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Chemotherapy for metastatic castration-sensitive prostate cancer
    Parimi, Sunil
    Chi, Kim N.
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (09) : 726 - 733
  • [47] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01): : 13 - 24
  • [48] COST-EFFECTIVENESS OF ABIRATERONE, ENZALUTAMIDE, AND APALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): A PARTITIONED-SURVIVAL MODEL
    Katta, A.
    Hansen, R. N.
    VALUE IN HEALTH, 2023, 26 (06) : S68 - S68
  • [49] Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer
    Swami, Umang
    Xie, Bin
    Young, Christopher
    Ramaswamy, Krishnan
    El-Chaar, Nader
    Gao, Wei
    Yang, Hongbo
    Wang, Yao
    Mucha, Lisa
    PROSTATE, 2024,
  • [50] Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
    Guven, Deniz Can
    Sayegh, Nicolas
    Tripathi, Nishita
    Erman, Mustafa
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345